Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | AR | P10275 | 6/20 | 0.52 |
| ▸ | F2R | P25116 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23200223 | 0.80 | MEN1 (0.51) | TSHRNPSR1ALDH1A1HPGDMAPT | |
| SCHEMBL16724727 | 0.79 | MEN1 (0.66) | TSHRF2RNPSR1ALDH1A1MAPT | |
| SCHEMBL23200081 | 0.78 | POLB (0.49) | TSHRNPSR1ALDH1A1HPGDMAPT | |
| SCHEMBL23200022 | 0.77 | DCUN1D1 (0.61) | ALDH1A1HPGDUBE2MDCUN1D1 | |
| SCHEMBL23200025 | 0.76 | UBE2M (0.60) | NPSR1ALDH1A1HPGDMAPTPKM | |
| SCHEMBL23200048 | 0.75 | ALDH1A1 (0.61) | NPSR1ALDH1A1HPGDMAPTPKM | |
| SCHEMBL9831966 | 0.75 | MAPT (0.48) | TSHRALDH1A1HPGDMAPTPKM | |
| SCHEMBL11693120 | 0.73 | ALDH1A1 (0.56) | F2RNPSR1ALDH1A1MAPTMEN1 | |
| SCHEMBL11692002 | 0.73 | MEN1 (0.54) | TSHRF2RNPSR1ALDH1A1MAPT | |
| SCHEMBL11695774 | 0.73 | EGFR (0.54) | NPSR1ALDH1A1MEN1KMT2AMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | claimed |
| EP-3802503-A1 | UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM | E-Therapeutics plc (GB) | 2021-04-14 | — | — | EP | claimed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| EP-3802503-A1 | UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM | E-Therapeutics plc (GB) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | TPH1, KYNU, TPH2 | TSHR 343/4885AR 4337/4885F2R 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.